In an era of never-ending outsourcing solutions and service providers, making that business-critical decision about your in-sourcing model for clinical programme management has never been so important. As every Biotech, Pharmaceutical and Medical Device company is unique, so too is their approach to clinical programme management.
There are occasions in which you favour running your project internally, but you may not have the specialist resource to operationalise your vision. Here you need a partner who not only understands the importance of quality, timing and budgeting when executing a clinical trial, but also one who understands the challenges small companies face on a daily basis.
Upsilon Global specialise in the selection and development of therapeutically-aligned clinical project teams for multi-country studies.
We focus on reducing the timelines, risks and costs associated with planning and launching clinical studies, acting as a virtual extension of your organisation and allowing you to conduct trials internationally without the fixed overheads, cost layers or multiple communication lines that come with using CROs.
Our insourcing process involves the specific selection of therapeutically-aligned and industry experienced professionals, allowing for centralised control running operations through your own SOPs.
Our lean and cost-effective solution enables you to collaborate with your required experts on an hourly or project-specific basis, alleviating common obstacles such as sickness & holiday pay, maternity leave, national insurance, bonuses and redundancy packages.
With time and success, company growth is inevitable, however the traditional risks and costs associated with expanding operations need not be. One of our major value propositions is being able to offer a cost-effective alternative to local/regional CROs. With our global operational presence and up-to-date knowledge of local and international regulatory affairs, Upsilon Global provides our partners with a virtual workforce covering 6 continents.
Whether you’re planning on entering the American market to offer supplementary backup studies to European sponsors, or you’re considering running trials across the MENA region, Upsilon Global can provide you with a cost-effective means to overcoming barriers to entry.
With the growth of outsourcing providers and the evolution of niche CROs, Sponsor’s now have a wealth of options when deciding whether to use a CRO, and subsequently which CRO to use.
For those wanting to engage with a full-service CRO, we partner with a selection of specialist research vendors offering a cost-effective solution to a full range of services. We select and recommend our partners based on operational excellence, quality metrics and therapeutic and study phase expertise. We select operational experts based on your study specific guidelines, whilst our CRO partner executes the study delivery.
Is your current CRO under-performing? Sometimes things don’t go as well as planned. All the while, your study must continue to deliver. Changing CROs mid-project can be a risky proposition. On the other hand, not switching CROs may present a greater risk to your project depending on a number of factors.
Under-performance can mean different things to different people. Whether it is timeline issues, quality of the work, high staff turnover, or unanticipated additional costs, your project can be at risk very quickly. If the under-performance is due to a root problem within the CRO, it may be time to make a change. Sometimes changing a function will fix the problem, and other times you may need to change providers completely. From the beginning of a project and throughout, it is smart to define how you will measure your CRO performance relative to expectations.
Upsilon Global engage with you, in confidence, to prepare replacement CRAs and/or a study management team, to take over the trial from your current CRO on an agreed date. We will provide you with replacement CRAs and if necessary a Project Manager, allowing you to prevent lost time and at minimal expense.